Abstract: Provided is a means effective in treating dermatomycosis. An external therapeutic agent for treating dermatomycosis containing a trialkali metal salt of citric acid.

Abstract: Provided is a means effective in treating dermatomycosis. An external therapeutic agent for treating dermatomycosis containing a trialkali metal salt of citric acid.

Abstract: The present invention provides a drug that is effective in treating and/or completely curing dermatophytosis with ease. More specifically, the present invention provides a dermatophytosis pharmaceutical composition characterized in that it is topically applied and includes, as a main active ingredient, at least one organic acid salt selected from the group consisting of ethylenediaminetetraacetic acid salts.

Abstract: A method for removing a heavy metal from sludge, including the step of putting the sludge into contact with a treating liquid to dissolve the heavy metal contained in the sludge into the treating liquid. The treating liquid is formed of either A or B, where (A) is an aqueous solution of phosphoric acid, and (B) is an aqueous solution of phosphoric acid containing at least one of B1 and B2, where (B1) is at least one acid other than phosphoric acid, and (B2) is at least one oxidant. The concentration of the phosphoric acid in the treating liquid is 3% by weight or more. Alternatively, the sludge is put into contact with the treating liquid at a temperature of 40.degree. C. or higher.

Abstract: Novel compounds represented by the formula ##STR1## wherein R.sup.1, R.sup.2, R' and R" are defined as hereinafter, having a blocking activity on .beta.-adrenergic nerves, novel intermediates useful for synthesis thereof and processes for preparing the same are disclosed. When substitution is at the 5-position and R.sup.1 and R.sup.2 are hydrogen, R' and R" are not simultaneously hydrogen and a 1 to 4 carbon atom alkyl group in the claimed compound.

Abstract: A glaucoma treating composition and method of treating glaucoma by administering the glaucoma treating composition to a patient are provided. The glaucoma treating composition comprises a carbostyril derivative, or acid addition salt thereof, having an intraocular pressure reducing activity in combination with an ophthalmically acceptable carrier, the barbostyril derivative being represented by the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each lower alkyl, and the carbon-to-carbon bond between the 3-position and the 4-position of the carbostyril skeleton is a single bond or double bond.

Abstract: Novel compounds represented by the formula ##STR1## wherein R.sup.1, R.sup.2, and R' and R" are defined as hereinafter, having a blocking activity on .beta.-adrenergic nerves, novel intermediates useful for synthesis thereof and processes for preparing the same are disclosed. When substitution is at the 5-position and R.sup.1 and R.sup.2 are hydrogen, R' and R" are not simultaneously hydrogen and a 1 to 4 carbon atom alkyl group in the claimed compound.

Abstract: Carbostyril derivative represented by the formula (I): ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom, a cycloalkylcarbonyl group, a cycloalkylalkanoyl group, a benzoyl group, an alkanoyl group or a phenylalkylcarbonyl group; R.sup.4 represents a hydrogen atom or an alkyl group, R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, an alkyl group, a cycloalkyl group, or a phenylalkyl group, or R.sup.5 and R.sup.6 may, when taken together with the nitrogen atom to which they are attached, form a 5- or 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen or oxygen atoms as hetero atoms; and the ring A has a partial structure: ##STR2## wherein R.sup.3 represents a hydrogen atom, a cycloalkylcarbonyl group, a cycloalkylalkanoyl group, a benzoyl group, an alkanoyl group or a phenylalkylcarbonyl group, with the proviso that at least one of R.sup.1, R.sup.2 and R.sup.3 when R.sub.

Abstract: 5-?1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives having the formula (I) ##STR1## wherein R.sup.1 represents an alkyl group having 1 to 4 carbon atoms and A, when taken together with the nitrogen atom to which it is attached, form a 5- or 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen, or oxygen atoms as hetero atoms, the pharmaceutically acceptable acid addition salts thereof, and a process for preparing the same.

Abstract: 5-[1-HYDROXY-2-(HETEROCYCLIC AMINO)]ETHYL-8-HYDROXY-3,4-DIHYDROCARBOSTYRIL DERIVATIVES REPRESENTED BY THE FORMULA (I) wherein A, when taken together with the nitrogen atom to which it is attached, forms a 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen, or oxygen atoms as hetero atoms, the pharmaceutically acceptable acid addition salts thereof, and a process for preparing the above compounds.

Abstract: 5-[1-Hydroxy-2-(substituted-amino)]alkyl -8-hydroxy-carbostyril derivatives represented by the formula (I) ##STR1## wherein R.sup.1 represents an alkyl group having 1 to 4 carbon atoms and R.sup.2 and R.sup.3, which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aralkyl group containing a straight or branched chain alkyl moiety having 1 to 4 carbon atoms or a cycloalkyl group having 4 to 6 carbon atoms, or R.sup.2 and R.sup.3 may, when taken together with the nitrogen atom to which they are attached, form a 5- or 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen, oxygen or sulfur atoms as hetero atoms, the pharmaceutically acceptable acid addition salts thereof, and a process for preparing the same.

Abstract: 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-substituted-carbostyril derivatives and 5-[1-hydroxy-2-(substituted-amino)]-alkyl-8-substituted-3,4-dihydrocarbost yril derivatives represented by the formulas (Ia) and (Ib) ##STR1## WHEREIN R.sup.1, R.sup.4 and R.sup.5 each represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, with at least one of R.sup.4 and R.sup.5 being an alkyl group, and R.sup.2 and R.sup.3, which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aralkyl group containing a straight or branched chain alkyl moiety having 1 to 4 carbon atoms or a cycloalkyl group having 4 to 6 carbon atoms, or R.sup.2 and R.sup.3 may, when taken together with the nitrogen atom to which they are attached, form a 5- or 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen, oxygen or sulfur atoms as hetero atoms, the pharmaceutically acceptable acid addition salts thereof, and a process for preparing the same.

Abstract: 5-[Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-carbostyril derivatives represented by the formula (I) ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aralkyl group containing a straight or branched chain alkyl moiety having 1 to 4 carbon atoms or a cycloalkyl group having 4 to 6 carbon atoms, or R.sup.1 and R.sup.2 may, when taken together with the nitrogen atom to which they are attached, form a 5 or 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen, oxygen or sulfur atoms as hetero atoms, the pharmaceutically acceptable acid addition salts thereof and a process for preparing the above compounds.

Abstract: 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives having the formula (I) ##SPC1##wherein R.sup.1 represents an alkyl group having 1 to 4 carbon atoms, and R.sup.2 and R.sup.3, which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aralkyl group containing a straight or branched chain alkyl moiety having 1 to 4 carbon atoms or a cycloalkyl group having 4 to 6 carbon atoms, or R.sup.2 and R.sup.3 may, when taken together with the nitrogen atom to which they are attached, form a 5- or 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen, oxygen or sulfur atoms as hetero atoms, the pharmaceutically acceptable acid addition salts thereof, and a process for preparing the same. These compounds posess a .beta.-adreno-receptor stimulating activity.

Abstract: 5-[1-HYDROXY-2-SUBSTITUTED-AMINO)]ETHYL-8-HYDROXY-3,4-DIHYDROCARBOSTYRIL DERIVATIVES REPRESENTED BY THE FORMULA (I) ##SPC1##wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aralkyl group containing a straight or branched chain alkyl moiety having 1 to 4 carbon atoms or a cycloalkyl group having 4 to 6 carbon atoms, or R.sup.1 and R.sup.2 may, when taken together with the nitrogen atom to which they are attached, form a 5 or 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen, oxygen or sulfur atoms as hetero atoms, the pharmaceutically acceptable acid addition salts thereof, and a process for preparing the above compounds.

Abstract: 2-Hydroxy-3-alkylaminopropoxycarbostyrils represented by the formula (I) ##SPC1##wherein R represents a straight or branched chain alkyl group having 1 to 4 carbon atoms useful as .beta.-adrenergic blocking agents and a process for preparing the same are disclosed.